The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma

被引:3
作者
Liang, Zhong-Guo [1 ]
Zhang, Fan [2 ]
Yu, Bin-Bin [1 ]
Li, Ling [1 ]
Qu, Song [1 ]
Li, Ye [1 ]
Guan, Ying [1 ]
Liang, Ren-Ba [1 ]
Han, Lu [1 ]
Zhu, Xiao-Dong [1 ]
机构
[1] Guangxi Med Univ, Canc Hosp, Dept Radiat Oncol, 71 He Rd, Nanning 530021, Peoples R China
[2] Univ New South Wales Sydney, St George Hosp, St George & Sutherland Clin Sch, Microbiome Res Ctr, Kogarah, NSW, Australia
基金
中国国家自然科学基金;
关键词
nasopharyngeal carcinoma; prognostic model; concurrent chemoradiotherapy; adjuvant chemotherapy; INTENSITY-MODULATED RADIOTHERAPY; PROGNOSTIC IMPACT; STAGING SYSTEM; 8TH EDITION; MULTICENTER; SURVIVAL; PHASE-3; CANCER; OUTCOMES; ERA;
D O I
10.2147/CMAR.S236128
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To construct a prognostic index (PI) for overall survival (OS) to stratify nasopharyngeal carcinoma (NPC) into high-risk and low-risk groups. We also applied the model to investigate the role of the addition of adjuvant chemotherapy (AC) to concurrent chemoradiotherapy (CCRT) regimens for the treatment of NPC. Methods: A prognostic model was established based on a retrospective study of 362 patients from January 2008 to June 2011. The discriminative and calibration abilities of the model were evaluated by Harrell's concordance index (C-index), and calibration curves. Bootstrapping was used to perform for internal validation. External validation was conducted using 324 patients diagnosed with NPC from July 2011 to December 2012 at the same institution. Survival analyses were performed between CCRT-AC and CCRT alone groups for the high-risk and low-risk groups. Results: The primary PI comprised covariates that were associated with OS in the training cohort, including T stage, N stage, age, and plasma alkaline phosphatase (ALP). Internal and external validation showed that the discrimination of the PI for OS was significantly better than that of the 8th edition AJCC staging system. Discretization by using a fixed PI score cut-off of 407.96 determined from the training data set yielded high- and low-risk subgroups with distinct OS outcomes in the validation cohort. Adjuvant chemotherapy improved OS in high-risk patients (HR 0.620, 95% CI 0.408 to 0.941; P = 0.023) but increased the risk of distant metastasis (HR, 4.222, 95% CI, 0.959 to 18.585; P = 0.038) in low-risk patients. Conclusion: The proposed prognostic model achieved good prediction and calibration of OS for patients with NPC. The addition of adjuvant chemotherapy might be a double-edged sword, bringing survival benefit to high-risk patients but greater risk of distant metastasis to low-risk patients.
引用
收藏
页码:801 / 812
页数:12
相关论文
共 30 条
[1]   Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer [J].
Badr, Mohamed ;
Joehrens, Korinna ;
Allgaeuer, Michael ;
Boxberg, Melanie ;
Weichert, Wilko ;
Tinhofer, Ingeborg ;
Denkert, Carsten ;
Schirmacher, Peter ;
Stenzinger, Albrecht ;
Budczies, Jan .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (09) :1443-1454
[2]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[3]   Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial [J].
Chen, Lei ;
Hu, Chao-Su ;
Chen, Xiao-Zhong ;
Hu, Guo-Qing ;
Cheng, Zhi-Bin ;
Sun, Yan ;
Li, Wei-Xiong ;
Chen, Yuan-Yuan ;
Xie, Fang-Yun ;
Liang, Shao-Bo ;
Chen, Yong ;
Xu, Ting-Ting ;
Li, Bin ;
Long, Guo-Xian ;
Wang, Si-Yang ;
Zheng, Bao-Min ;
Guo, Ying ;
Sun, Ying ;
Mao, Yan-Ping ;
Tang, Ling-Long ;
Chen, Yu-Ming ;
Liu, Meng-Zhong ;
Ma, Jun .
EUROPEAN JOURNAL OF CANCER, 2017, 75 :150-158
[4]   Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial [J].
Chen, Lei ;
Hu, Chao-Su ;
Chen, Xiao-Zhong ;
Hu, Guo-Qing ;
Cheng, Zhi-Bin ;
Sun, Yan ;
Li, Wei-Xiong ;
Chen, Yuan-Yuan ;
Xie, Fang-Yun ;
Liang, Shao-Bo ;
Chen, Yong ;
Xu, Ting-Ting ;
Li, Bin ;
Long, Guo-Xian ;
Wang, Si-Yang ;
Zheng, Bao-Min ;
Guo, Ying ;
Sun, Ying ;
Mao, Yan-Ping ;
Tang, Ling-Long ;
Chen, Yu-Ming ;
Liu, Meng-Zhong ;
Ma, Jun .
LANCET ONCOLOGY, 2012, 13 (02) :163-171
[5]  
D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO
[6]  
2-B
[7]  
Dong YY, 2016, STRAHLENTHER ONKOL, V192, P394, DOI 10.1007/s00066-016-0970-3
[8]   Survival outcome of patients with nasopharyngeal carcinoma: a nationwide analysis of 13407 patients in Taiwan [J].
Huang, W. -Y ;
Lin, C. -L ;
Lin, C. -Y ;
Jen, Y. -M ;
Lo, C. -H ;
Sung, F-C ;
Kao, C-H .
CLINICAL OTOLARYNGOLOGY, 2015, 40 (04) :327-334
[9]   The Role of Adjuvant Chemotherapy After Definitive Chemoradiation Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma in a Non-endemic Area: Multi-institutional Retrospective Study Using Propensity Score Matching Analysis [J].
Kim, Y. S. ;
Ahn, Y. C. ;
Lee, C. G., Jr. ;
Cho, K. H. ;
Moon, S. H. ;
Wu, H. G. ;
Oh, Y. T., Sr. ;
Chung, W. K. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05) :1326-1326
[10]   Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma [J].
Li, Guo ;
Gao, Jin ;
Tao, Ya-Lan ;
Xu, Bing-Qing ;
Tu, Zi-Wei ;
Liu, Zhi-Gang ;
Zeng, Mu-Sheng ;
Xia, Yun-Fei .
CHINESE JOURNAL OF CANCER, 2012, 31 (04) :197-206